Abstract | Remyelination in the CNS is the natural process of damage repair in demyelinating diseases such as multiple sclerosis (MS). However, remyelination becomes inadequate in many people with MS, which results in axonal degeneration and clinical disability. Enhancement of remyelination is a logical therapeutic goal; nevertheless, all currently licensed therapies for MS are immunomodulatory and do not support remyelination directly. Several molecular pathways have been identified as potential therapeutic targets to induce remyelination, and some of these have now been assessed in proof-of-concept clinical trials. However, trial design faces several obstacles: optimal clinical or paraclinical outcome measures to assess remyelination remain ill-defined, and identification of the ideal timing of therapy is also a crucial issue. In addition, realistic expectations are needed concerning the probable benefits of such therapies. Nevertheless, approaches that enhance remyelination are likely to be protective for axons and so could prevent long-term neurodegeneration. Future MS treatment paradigms, therefore, are likely to comprise a combinatorial approach that involves both immunomodulatory and regenerative treatments.
Since the first IFNβ preparation was licensed for the treatment of multiple sclerosis (MS) in 1995, a revolution has taken place in the development of MS-specific therapies. The MS therapeutics currently licensed in the USA and Europe employ ten different mechanisms of action, and another therapy is expected to be available before the end of 2017. All these agents target the immune system, either via immunosuppression or via immunomodulation, owing to the assumption that MS is caused by autoimmune-mediated demyelination of the CNS 1, 2 . After a demyelinating attack, remyelination -an endogenous program invoked to repair tissue damage -is commonly triggered. However, this program fails or is insufficient in many patients with MS, resulting in important consequences such as subsequent vulnerability to axonal degeneration and consequent progression of clinical disability. Thus, a treatment that promotes remyelination would be desirable for patients with MS.
Remyelination in acute experimental animal models of MS is reliable and efficient 3, 4 and several molecular pathways that invoke this program have been defined 5, 6 . However, whether these experimental data are directly transferable to human MS is unclear. Potential therapeutic approaches could involve several general mechanisms that either directly target cells of the oligodendrocyte lineage, or indirectly affect these cells via T cells or other glial cells (FIG. 1) . Mouse experiments have enabled the characterization of some important factors that influence remyelination (FIG. 2) . In addition, a number of putative molecular targets for enhanced remyelination have been described in mice, with several promising therapeutic candidates identified 5, 6 . As a consequence of this research, the monoclonal antibody opicinumab (which targets LINGO1), the antimuscarinic drug clemastine, and erythropoietin all have been tested in ran domized controlled clinical trials (TABLE 1) . Unfortunately, the results of all these early phase trials were unimpressive, although some suggestive benefits were reported that could prompt further investigation. In addition to these completed trials, several other trials are currently underway or planned (TABLE 2) . Consequently, it is timely to review our current knowledge of remyelination in MS, what we have learned from a clinical perspective, how future trials involving remyelinating strategies should be designed, and what expectations we can have from this therapeutic approach.
The value of remyelination
In the physiological state, both myelinated and unmyelinated axons are found in the CNS. Classic teaching was that myelin thickness is dependent simply on axonal diameter, with a fixed ratio maintained between axonal
G-ratio
The ratio of the inner axonal diameter to the total outer diameter, an index of relative myelin thickness
Uhthoff's phenomenon
Heat-associated worsening of neurological symptoms caused by inhibition of nerve conduction following demyelination.
Shadow plaques
Multiple sclerosis lesions in which the total lesion area is remyelinated.
diameter and myelin thickness (the g-ratio), and that myelin thickness in turn influences internodal length and, consequently, the speed of saltatory conduction. Evidence obtained in the past few years shows that these principles do not always hold true. For example, in the auditory pathway, axons that transmit signals in response to low-frequency sound have thicker myelin sheaths, but shorter internodes, than the axons that are stimulated in response to high-frequency sound 7 . This example demonstrates that myelin almost certainly assists in the efficient temporal processing of axonal signals and suggests that precise regulatory mechanisms govern myelin sheath formation. Other important functions of myelinating oligodendrocytes include the supply of trophic factors for the axon and protection against inflammatory attack 8, 9 . After damage, new myelin segments arising as part of a remyelinating program are thinner and shorter than the original segments, resulting in reduced distances between adjacent nodes of Ranvier. In addition, a study in a mouse model of toxic demyelination showed that network functions might not recover completely in the presence of cortical demyelination 10 . These observations raise the question of what remyelination can achieve. A perfect repair process would entail the reconstitution of myelin thickness, internodal segmental length and distribution of ion channels to levels identical to those present before injury, but this aim is unlikely to be achievable even when remyelination is promoted by a treatment. Thus, we must lower our expectations of what remyelin ation can achieve in a disease like MS. Nevertheless, even an imperfect myelin sheath will improve conduction velocity and, thus, could improve functional recovery. Theoretically, this benefit could encompass reduced fatigue and resolution of Uhthoff's phenomenon. In the long term, an intact axon-myelin unit could protect the axon from further degeneration or at least slow the rate of neurodegeneration. Consequently, the primary logic for therapeutic enhancement of remyelination is to diminish future clinical disability.
The course of remyelination in MS
Although the presence of remyelination in MS lesions was debated for a long time, strong evidence of remyelin ation was provided by electron microscopy [11] [12] [13] . MS lesions can be completely or only partly remyelinated, and the remyelinated areas are frequently -but not exclusively -located at the lesion border. However, differentiation between partly demyelinated and remyelin ated axons in human MS samples can be difficult, as no histological marker is available that can unequivocally distinguish between newly formed and pre-existing myelin. In routine histology of MS tissue, the intensity of myelin staining and the thickness of the myelin are used to identify remyelination, although these measures are imperfect owing to the fact that the resolution of light microscopy is usually insufficient to measure internodal length or axon diameter (FIG. 3) . The best indicator of remyelination in animal studies is electron microscopy, which enables the measurement of myelin thickness relative to axonal diameter. However, even electron microscopy is not always a reliable method to identify remyelinated axons 14 . Axons are remyelinated by adult oligodendroglial progenitor cells (OPCs) that differentiate into myelinating oligodendrocytes in response to a demyelinating stimulus. The extent of remyelination can differ from lesion to lesion, even within the same patient, depending on lesion location [15] [16] [17] . However, one histological study identified subgroups of patients with MS who have either extensive or limited remyelination, suggesting that individual factors also influence the capacity of lesions to remyelinate 15 . The reasons for differential capacity for remyelination depending on lesion location are unclear, but intrinsic differences within the OPC population or the extracellular milieu could contribute to this phenomenon. Interestingly, transcriptionally heterogeneous oligodendroglial subtypes have been identified in the mouse CNS, and individual OPC populations were found to be enriched in certain brain regions 18 . In addition, mouse neural precursor cells within the subventricular zone were demonstrated to have the capacity to differentiate into oligodendrocytes with superior remyelination capa city in comparison to that of oligodendrocytes emanating from parenchymal OPCs 19 . These neural precursor cells have a restricted migration capacity, which potentially explains some of the observed regional heterogeneity in remyelination capacity. Interestingly, recruitment of the neural precursor cell population can be enhanced by either genetic or pharmacological inhibition of Gli1, a transcriptional regulator of the sonic hedgehog pathway, which might represent a molecular mechanism that can be invoked for therapeutic purposes 20 . Remyelination occurs frequently in active, demyelinating lesions -the initial phenotype of established MS lesions. Remyelination is also a common phenomenon in tissue samples from patients with MS who have short disease durations, but is less frequent in samples from patients with chronic disease, in whom only ~20% of the lesions are completely remyelinated (forming so-called shadow plaques) 15, 17, 21 . As discussed previously, the histological identification of ongoing remyelination in MS is difficult, as determining when the new myelin sheath was formed is currently impossible. One cogent experimental approach to identify ongoing remyelination uses markers that label oligodendroglia at different stages
Key points
• CNS remyelination serves to limit and repair the damage in demyelinating diseases such as multiple sclerosis (MS) • Several intrinsic molecular pathways that execute endogenous remyelination have been identified and are potential therapeutic targets • The first clinical proof-of-concept trials to enhance remyelination in MS have been conducted in the past few years • The optimal clinical and paraclinical outcome measures for the assessment of remyelination are not known, but neurophysiological measures, MRI, myelin-targeted PET radiotracers, and optical coherence tomography all are possible adjuncts to clinical outcomes in proof-of-concept studies • The timing of remyelination therapy is a crucial issue • Future MS therapy is likely to involve a combination of immunomodulatory and regenerative treatments of maturation. Results from such experiments suggest that remyelination is initiated immediately after onset of demyelination but is rare or absent in inactive MS lesions that have been present for months or years 22 . Similar dynamics have been identified in mouse models of demyelin ation and remyelination. In zebrafish, individual oligodendrocytes have a very narrow time window of 5 h in which to complete the formation of internodes 23 . On the other hand, Chen and colleagues used MRI techniques to examine the brains of patients with MS, and observed significant increases in voxel-based magnetization transfer ratio (MTR, discussed later in the article), consistent with remyelination, for approximately 7 months after initial MS lesion formation 24, 25 . Experimental studies in a mouse model of spinal cord injury also suggest that, although the length of the myelin sheaths is short in the early remyelinative phase, sheath length and thickness increase to almost match those of uninjured controls during the following 6 months, suggesting that some refinement of remyelination can occur in the subacute phase 26 . Although variation is present between species, the available data suggest that remyelination is initiated promptly and is subject to later refinement, but stops within weeks to months of its commencement within a given region, and is unlikely to occur in long-standing, chronic lesions.
Mechanisms and failure of remyelination
Remyelination is a complex biological process that requires the orchestrated interaction of intrinsic and extrinsic signalling molecules and pathways. A prerequisite for remyelination is the presence of functionally intact axons, as well as OPCs that can differentiate, establish contact with and ensheath axons, and can also form compact myelin. Differentiation and migration of oligodendroglia are markedly impaired in long-lasting chronic MS lesions, resulting in insufficient remyelination [27] [28] [29] . Oligodendrocytes can form multilayered membranes around nanofibres that have comparable physical properties to axons [30] [31] [32] ; however, electrically active axons are preferentially myelinated 33, 34 . This interaction between axons and oligodendrocytes partly depends on synaptic and non-synaptic vesicular release of glutamate 23, 33, 35 . Axonal glutamate release promotes remyelination via the induction of OPC differentiation 36 . Furthermore, the promyelinating capacity of axonal activity is potentiated by the cytokines neuregulin-1 (NRG1) and brain-derived neurotrophic factor (BDNF), demonstrating interdependency between cytokine-based and activity-initiated stimuli 37 . These findings from in vitro and animal studies demonstrate the close interaction between axons and oligodendrocytes during myelination and remyelination, and also stress the fundamental importance of functionally intact axons in guiding the outcome of remyelination. This interaction is especially important in the context of MS, in which axons are frequently injured and little is known about the functionality of demyelinated axons. In addition to the presence of functional, intact axons, the timely migration and differentiation of OPCs into myelinating oligodendrocytes is a prerequisite for successful remyelination. OPCs accumulate at the borders rather than within the body of MS lesions, suggesting a disturbed migration of OPCs 27 . During development, OPC migration is regulated by short-range molecules expressed predominantly in the local extracellular milieu, such as laminin, fibronectin, vitronectin, and tenascin 38 , and diffusible molecules such as netrins, semaphorins, and hepatocyte growth factor receptor. Histological studies have shown via immunochemistry that a migration-promoting environment in active demyelinating lesions shifts to a less favourable milieu in long-lasting lesions 27, [39] [40] [41] [42] [43] [44] . The differentiation of OPCs into mature myelinating oligodendrocytes is also frequently impaired in MS, especially in long-lasting MS lesions 22, 30, 29 . The differentiation of these cells is regulated by intracellular signalling cascades and transcription factors, such as OLIG1, OLIG2, SOX10 and MYRF 45 . A combination of in vitro and animal experiments have identified several intra cellular signalling cascades that contribute to the regulation of oligodendroglial differentiation and remyelination, such as WNT, LINGO1 or retinoic acid receptor-γ signalling [46] [47] [48] [49] [50] (FIG. 2; TABLE 3 ). Other pathways stimulating oligodendroglial differentiation have emerged in compound screens using rat or mouse OPCs. For example, benzatropine and clemastine promoted oligodendroglial differentiation via muscarinic receptor antagonism and miconazole via phosphory lation of ERK1 and ERK2 [51] [52] [53] . In addition to remyelin ation being promoted by direct modulation of pathways within oligodendrocytes, the process is also modulated by para crine factors. The removal of myelin debris by phagocytes is known to be required for initiation of remyelination 54 . Experiments in mouse models have shown that the Nature Reviews | Neurology Remyelination requires the proliferation of oligodendrocyte precursor cells (OPCs), migration into the demyelinated area, differentiation into myelinating oligodendrocytes, and production of functional myelin. This process can be supported by direct modulation of OPCs, removal of inhibitory factors, or by indirect modulation via astrocytes, microglia or other infiltrating cells such as macrophages or T cells.
Heterochronic parabiosis
Surgical joining of two animals of different ages to generate a shared circulation.
capacity of macro phages and microglia to phagocytose myelin decreases with age and, consequently the capacity for remyelin ation also decreases. Accordingly, impaired phago cytosis of myelin in aged animals can be circumvented by heterochronic parabiosis resulting in the 'rejuvenation' of remyelination 55 . Finally, several molecules have been well-characterized as inhibitors of myelination, including extracellular matrix proteins such as chondroitin sulfate proteoglycans and hyaluronan 56, 57 .
Enhancement of remyelination Possibilities and caveats of remyelination enhancement.
Remyelination can be enhanced in the CNS using several strategies, and a number of putative therapeutic targets have also been identified that remain to be tested. As described in previous sections, myelin debris and impaired myelin phagocytosis delays remyelination. Thus, modulation of phagocytotic cells could, in principle, promote remyelination by creating a receptive microenvironment. Although this idea has been shown to work experimentally 58 , a drug that specifically modifies resident microglia or infiltrating macrophages for therapeutic benefit is not currently available. Clearly, care should be taken in adopting such an approach, as overactive phagocytosing cells could cause further damage.
The role of astrocytes in the development and resolution of MS lesions has not yet been resolved. Astrocytes can produce both pro-inflammatory and anti-inflammatory factors, and thus whether astrocytes are friend or foe has long been debated 59, 60 . Data from toxic demyelin ation studies in mice show that astrocytic signalling is necessary to fully activate microglia, which in turn are required to phagocytose myelin debris to enable remyelination 61 . However, the role of astrocytes is prob ably complex, and cell-cell interactions between astrocytes and microglia, infiltrating macrophages, and T cells are not yet fully understood. Furthermore, as with microglia, no drugs are currently available that can specifically modulate astrocytes.
A direct target for modulation of remyelination is the OPC itself. Remyelination can be promoted either by improvement of the migration of these cells to recruit more OPCs to sites of demyelination, or by enhancement of the subsequent proliferation and maturation of OPCs to increase the number of oligodendrocytes available to myelinate axons. Targeting one or more of these steps seems to be feasible and experimental studies have provided proof of principle; for example, in a mouse model of demyelination, cytidine 5ʹ-diphosphocholine was shown to increase OPC proliferation and thus increase the speed of remyelination 62 . However, the exact reason why remyelination is insufficient in MS is not clear; therefore, which of these steps is rate limiting is currently unknown. Furthermore, the rate-limiting step could vary between individuals and between lesions in any given patient. Examination of MS lesions suggests that insufficient migration of OPCs into the lesion and a lack of differentiation can both be present 22 . Whether these deficits are due to an error within the OPC differentiation program or are due to the lack of external signals or the presence of inhibitory factors within the lesions is not known. In principle, these signals can be derived from
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Figure 2 | Summary of molecular factors controlling remyelination. Remyelination is a complex process that requires close orchestration of many factors that promote oligodendrocyte precursor cell (OPC) proliferation, migration, and differentiation. Each of these steps is controlled by a number of factors and signalling pathways that could be supportive or inhibitory. The summary presented here represents a highly simplified view, and many other factors are likely to be involved. Data derived from animal experiments and from human tissue might also be complementary, reflecting phylogenetic differences. BDNF, brain-derived neurotrophic factor; BMP, bone morphogenic protein; CSPG, chondroitin sulfate proteoglycan; CXCL1, growth-regulated α-protein; CXCL2, C-X-C motif chemokine 2; CXCL12, stromal cellderived factor 1; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IGF1, insulin-like growth factor I; LIF, leukaemia inhibitory factor; LINGO1: leucine rich repeat and immunoglobulin-like domain containing protein 1; PDGF, platelet-derived growth factor; PSA-NCAM, polysialylated neural cell adhesion molecule; RXRγ, retinoic acid receptor-γ.
any of the other cell types within a lesion. As mentioned previously, microglia are important for the phagocytosis of myelin debris; in addition, microglia and astrocytes both produce a number of important factors required for successful remyelination 63, 64 . However, we currently do not have specific substances that can selectively target these cells.
In addition to the promotion of endogenous repair mechanisms, remyelination might also be achieved by administration of exogenous OPCs. An initial suite of experiments indicated that these cells could directly myelinate demyelinated axons 3 . Studies from the past few years support the concept that other precursor cells, including mesenchymal stem cells and the derivatives of induced pluripotent stem cells, can also create an environment that promotes remyelination 65 . Which type of stem cells (neural, mesenchymal, and so on) would be the best choice and how they should be administered (for example, intravenously, intrathecally, or into the lesion) remains an actively debated topic. However, the transplantation of remyelinating cells directly into lesions is probably not practical in MS, as this pro cedure would potentially require stereotactic injections at numerous sites. When mesenchymal stem cells are administered intravenously, the effect could be mediated via modulation of the immune system without direct effects on remyelination and thus could be classed as an immunomodulatory treatment rather than a remyelinating treatment 66 .
Remyelination therapies: expectations and optimal delivery. High expectations have been placed on new therapeutic approaches such as remyelinating therapies for MS to influence long-term disease outcomes from both a clinical and quality of life perspective. The benefits that can be derived will be predicated on the magnitude of the direct and indirect biological effects, the timing of the therapeutic regimen, and the pathological context in which the therapy is applied. An obvious but important point to raise is that remyelinating therapy will only be effective when and where demyelination is extant; however, emerging evidence suggests that MS pathology is not always accompanied by demyelination 67 . This finding indicates that application of robust paraclinical measures that quantitate the degree of demyelination on both a regional and global scale will be important to identify the patients in whom a remyelinative approach is likely to be beneficial and, therefore, to whom this treatment should be administered.
In addition, our expectations for remyelinative therapy might only be realised by adopting strategies that target multiple components of the myelination cascade. 
Optical coherence tomography
An optical imaging method that provides detailed information regarding the microstructure of thin layers of tissue (for example, the retina) based on backscatter of reflected light.
In a heterogeneous disease such as MS, a singular deficit is unlikely to apply to all lesions; enhancement of OPC recruitment might be appropriate in certain circumstances, whereas enhancement of the extent or the quality of myelination might be sufficient in other contexts. Reorganization of axonal ion channels to cluster at the new nodes formed by remyelination will also be a necessary component of functional recovery. Therapeutic approaches that serve to initiate the entire myelin ation cascade, enabling downstream events to be driven autonomously, might, therefore, be the most likely to be broadly beneficial. However, this approach would have to be modified in circumstances where myelination block is the predominant issue. Remyelination starts immediately after demyelination has occurred and the process can last for up to 6-7 months, as indicated by imaging studies in humans 25, 68 . Nevertheless, all experimental studies suggest that the most important molecular switches that establish the remyelination program are probably set within the first few weeks of the process 69 . Thus, the most appropriate time to initiate a remyelination-promoting therapy seems to be immediately after immune damage. Consistent with this view, most current trial designs apply investigational drugs after a relapse. Optic neuri tis has emerged as a favoured clinical presentation to assess remyelinative therapies as its presenting features are fairly stereotyped and several good clinical outcome parameters are avail able, as well as robust neuro physiological tests and optical coherence tomography (OCT), by which to assess outcome.
The downstream benefits of increased remyelin ation could be multifaceted, including the direct promotion of functional recovery and a reduction in the risk of secondary axonal degeneration. However, limiting axonal degeneration might not have direct clinical bene fit after a single relapse but could enable the maintenance of axonal reserve and thus provide a protective effect against clinical disability arising from subsequent disease activity affecting the same neural pathway. Consequently, treatments that promote remyelin ation might not necessarily improve clinical recovery from an individual relapse but could still provide meaningful long-term benefits by delaying the onset of the progressive phase of the disease. Although most investigators would agree that a remyelin ating treatment should start as soon as possible after a demyelinative event, uncertainty remains as to whether confining the use of such treatment to immediately after clinical relapses will be sufficient or, for that matter, wise. Many new lesions are known to develop in the early relapsing-remitting phase of MS, in the absence of clinical signs and symptoms 70 . Although lesions that result in clinical disability could be argued to be more important on the basis of their severity or their targeting of eloquent pathways, the cumulative pathology resulting from asymptomatic lesions, as well as changes in so-called normal-appearing white matter, will almost certainly also contribute substantially to long-term disability. Consequently, ongoing application of a treatment in the early, relapsing-remitting phase of the disease would have the advantage that clinically silent lesions would also be treated.
Whether repair is possible in lesions that have been demyelinated for a long time will also be an important point to determine. Results from a trial in which patients with long-standing optic neuritis were treated with clemastine 71 (TABLE 1) indicate that we might be able to achieve at least a small functional improvement in such patients. However, whether the improvement in this trial was actually mediated via remyelination or whether it was dependent upon other mechanisms is not entirely clear.
Another important point is that, during the progression of MS, the CNS pathology becomes less a consequence of sporadic, peripheral immune attack and more the consequence of evolving neuropathology in normal-appearing white and grey matter. The reasons for this switch are unknown. Consequently, ongoing treatment would be the most logical approach in the subsequent progressive phase of the disease; however, this approach assumes that the symptoms of this phase result from demyelination. In reality, the underlying cause of the progressive phase remains unclear, and it might instead be driven by neurodegeneration.
Despite the potential benefits, the provision of continuous remyelinative therapy could have adverse consequences. For example, if the therapy directly induced en masse maturation of oligodendrocyte progeni tors it could result in depletion of this cellular pool. This potential issue could be addressed by the administration of remyelinative treatments on an ongoing basis but as pulse therapy, thereby enabling the progenitor population sufficient time to re-expand between treatments. Such an approach could still present difficulties in the relapsing-remitting phase of the disease if the pulse therapy is not delivered in concordance with temporal peaks in demyelinative activity, especially if treatment must be delivered within a narrow window of opportunity to optimize its remyelinative potential. However, results from the trial of clemastine delivered in the context of chronic optic neuritis suggest that this concern might be unnecessary, given that chronically demyelin ated axons seemed to remain responsive -although whether their responsiveness is quantitatively diminished is unknown. One valuable future development would be a way to routinely assay a cost-effective peripheral marker of the real-time global level of myelin breakdown (for example, myelin basic protein fragments in the blood) and to deliver remyelinative therapy when the levels rise. However, to date, no marker has been identified that reliably predicts demyelination.
Another theoretical risk is that inappropriate axons could be myelinated, resulting in a 'dysmyelinating' pheno type that could compromise functional recovery by interfering with coordinated axonal transmission within neural networks. This risk could be addressed by combining the remyelinative therapy with physiotherapy or transmagnetic stimulation to promote activity-dependent myelination. FGF, fibroblast growth factor; LINGO1, leucine rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein-1; MS, multiple sclerosis; OPC, oligodendrocyte precursor cell; PSA-NCAM, polysialylated-neural cell adhesion molecule; RXRγ, retinoid X receptor-γ.
Diffusion-weighted MRI
An MRI method in which the contrast-reflecting tissue microstructure is determined based on intrinsic local differences in the rate or extent of diffusion of water.
b-value
A scanner parameter conveying the relative strength and timing of the diffusionsensitising gradients for diffusion-weighted MRI; stronger diffusion effects are imaged with higher b-values.
Q-ball imaging
A form of diffusion MRI developed by Dr David Tuch of Harvard University, USA, which enables multiple white matter fibre orientations to beresolved even within a single voxel.
Magnetization transfer imaging
An imaging method based on the intrinsic contrast provided by differences in the extent of transfer of magnetisation from a macromolecular bound water pool (for example, myelin water) to the bulk water when radiofrequency energy is applied to the bound water pool.
Finally, the stimulation of proliferation in OPCs or other progenitor cells could lead to the development of uncontrolled growth and tumours. Fortunately, animal studies investigating the various pathways for remyelination have not, thus far, indicated that tumour growth is a common outcome of remyelinative treatments 65 . However, safety data from the long-term administration of these treatments are not yet available and will need to be acquired if and when these interventions are applied. 72 . The classic observations of the slowing and subsequent recovery of visual evoked potential latency after optic neuritis have been interpreted as evidence for demyelination and subsequent remyelination 73 . Although measures of latency are generally stable in asymptomatic patients, differences over time correspond with behavioural changes in visual contrast sensitivity 74 . However, interpretation of the changes in latency as evidence of demyelination is not unequivocal: for example, such changes could also reflect redistribution of ion channels 75 . Complementary information concerning the axonal loss associated with demyelination is provided by the amplitude of the evoked response. Visual evoked potential measurements can be highly reproducible, although additional systematically acquired data are needed in people with MS to validate their use in this context 76 
Assessment of myelination in MS
Several approaches have been proposed for non-invasive assessment of demyelination and remyelination. Evoked potentials have been used for the evaluation of patients with MS for decades, although these measures have only been employed as a quantitative outcome measure for monitoring myelination or remyelination within the past few years
.
In the past few years, OCT measures of retinal nerve fibre layer thickness have provided a more direct measure of axonal loss associated with inflammatory demyelin ation in the anterior visual tract 77 than can be provided by visual evoked potentials. OCT methods are quantitative and reliable in test-retest studies; moreover, OCT imaging systems are already widely available and used routinely in ophthalmology clinics 78 . The low cost and ease of OCT measurements makes them attractive as outcome measures in clinical trials, although they limit trial designs to the assessment of demyelination and remyelination in the anterior visual pathways.
A number of MRI methods are sensitive to demyelination-remyelination across the whole brain and spinal cord 79, 80 owing to the effects of myelin on the imaging characteristics of water. Water associates reversibly with the exposed polar amino acids of myelin proteins to create a loosely bound compartment that is in exchange with free tissue water. Although relatively insensitive to change, signal intensity on conventional T2-weighted imaging reflects myelin density because of this 'bound' water component 81 ; myelin-bound (associated) water exhibits a shorter T2 relaxation time than that of intracellular or extracellular free water. The proportion of the total brain water in an imaging voxel that is in the rapidly relaxing component of bound water can be estimated from analysis of serially acquired images using a range of methods, although all are based on the assessment of differences in T2 relaxation 82 . Validation experiments ex vivo have shown strong correlations between the bound water fraction and myelin content 83 .
Longitudinal studies in vivo have demonstrated variable recovery of this myelin-associated water content in individual lesions after an acute demyelinating episode in MS 84 . New, fast imaging methods (including stimulated echoes amplitude modulation (STEAM)-based echo planar imaging or fast acquisition with spiral trajectory and T2prep (FAST-T2)) now enable whole-brain imaging in a clinically practical time frame 85 . Combination of information on the myelin-bound water pool with measures of total tissue water from MRI proton density imaging enables estimates of the g-ratio in highly oriented white matter, such as the spinal cord 86 . Diffusion-weighted MRI is sensitive to the relative directional diffusion of water molecules, and diffusion tensor imaging (DTI) -a type of diffusion-weighted MRIcan be used to map the integrity of white matter tracts in the brain and spinal cord. In bulk water (for example, in the ventricular cerebrospinal fluid), rates of diffusion are equal in all directions (isotropic diffusion). However, water molecules associated with myelin proteins are constrained in their diffusion. Axons and myelin particularly restrict diffusion transverse to their axis (anisotropic diffusion). Measures of mean diffusivity increase with demyelination, and measures of directionality (fractional anisotropy) decrease with demyelination 87 . Increases in fractional anisotropy also can be seen over time, which have been interpreted to reflect possible remyelination 88 . The specificity of diffusion imaging for myelin can be increased by using advanced data acquisition sequences (for example, high b-value imaging) that maximize sensitivity to diffusion and spatial and angular resolution, and by using advanced analysis methods (such as diffusion spectrum imaging or q-ball imaging) that are not yet routine in clinical scanning 89, 90 . Currently, the most widely used MRI method in the detection of demyelination-remyelination is magnetization transfer imaging. This technique relies on differences in the resonance frequencies of water molecules associated with myelin proteins relative to those of free water, and on the spin 'memory' (a property that is related to the water spin-lattice relaxation time, T1) of these water protons, for magnetization saturation introduced by the imaging sequence. Magnetization 'tagging' of myelin-associated water molecules is performed by applying increased power selectively to the myelin-bound water by using a radiofrequency that is different from the resonance frequency for the free water, but within the broader range of frequencies for bound water, which eliminates signal from the myelin-bound water. As these tagged, myelin-bound molecules exchange with free water, the MRI signal of the free water is reduced. The greater the myelin content, the greater the net exchange of the magnetization-tagged molecules, and the greater the decrease of the free-water signal (FIG. 4) . By subtracting an image made with the tagging sequence 'on' from that with it 'off ' , an image can be created of the relative contribution of the exchanging water (myelin bound) pool 91 .
Empirical correlations with post-mortem brains and preclinical studies have validated the relative magnetization transfer (that is, the MTR) as an index of myelin 92 . The precision of the measurement and low test-retest variance on a given scanner suggest that well-powered studies might demand only modest numbers of participants in order to demonstrate its efficacy in quantifying myelination in patients with MS 93 ; indeed, a phase II trial demonstrated the use of MTR as an end point for assessment of efficacy of a novel molecule intended to promote remyelin ation 94 . However, absolute myelin content cannot be estimated from MTR measures, as it is also influenced by water content, inflammation and axonal loss 84, 92 . Consequently, although MRI measures of myelin water, diffusion and magnetization transfer share common general relationships with myelin content, they are not directly comparable 95 . Molecular imaging of myelin with PET has been explored within the past few years in an effort to provide a more direct measure of myelin levels than is provided by MRI. PET involves reconstruction of an image of the tissue of interest on the basis of brain uptake of an injected tracer molecule labelled with a positron-emitting isotope (typically 11 C or 18 F) that binds to a myelin protein 96 . PET radiotracers that bind to brain amyloid have also been shown to bind to myelin 96 ; for example, differences in binding of the amyloid radioligand N-methyl-[
in the brains of people with MS are consistent with expected patterns of white matter demyelination that are predicted on the basis of MRI scans acquired at the same time. Despite the lower spatial resolution of PET (typical linear resolution of 3-5 mm, depending on acquisition methods and signal) relative to that of MRI, the sensitivity of PET seems to be sufficient to monitor myelin changes over follow-up periods of as short as a few months 97 . To date, few evaluations have been published of myelin mapping by amyloid radiotracers other than Pittsburgh compound B; however, there is no reason to believe that other commercially manufactured, fluorinated amyloid radiotracers -such as florbetapir, flutemetamol or florbetaban -cannot also be used as myelin imaging agents. Myelin PET imaging for patients with MS using amyloid radiotracers could, therefore, build on the infrastructure and experience available for the use of these compounds in the diagnosis of early Alzheimer disease. New, more-specific agents such as 11 C-labelled N-methyl-4,4ʹ-diaminostilbene ([ 11 C]MeDAS; or a fluorinated derivative of the same structure) 98 that bind more strongly to myelin than Pittsburgh compound B promise even greater sensitivity. PET ima ging is of great interest because it provides a measure that directly reflects myelin content; however, investigators have so far only been able to generate maps of rela tive myelin content. The low spatial resolution of PET might also confound estimation of the myelin content in small lesions, owing to partial volume effects.
The measures of myelin content that are now available for use in clinical research each reflect different properties of myelin. These measures probably have different dynamic ranges and different sensitivities to change -although these differences have not yet been explored formally. In order to take advantage of the complementary strengths of different modalities, an argument could be made for the inclusion of multiple measures in clinical trials of remyelinating therapies that intend to provide mechanistic proof of concept, rather than relying solely on one measure. For example, in conjunction with baseline and end point PET measures of relative myelin content, serial MRI could be used to monitor the time course of lesion evolution 99 , along with measures of innate immune activation in individual lesions 100 that are intended to model their individual potential for remyelination. As intact axons are needed to support remyelination, measures of relative axonal density from magnetization transfer 101 , diffusion ima ging 102 or magnetic resonance spectroscopy could contribute to these analyses.
Conclusions
Owing to the large number of available MS immunomodulatory therapies with different modes of action, many experts believe that the scope to develop truly novel immune therapies is limited. Despite this armamentarium of treatments, none is currently able to silence the disease completely, as demonstrated by the continued propensity for clinical disability in a substantial proportion of patients, even with the long-term use of these agents and the apparent control of the accumulation of inflammatory lesions arising from their use. Consequently, the development of neuroprotective and regenerative treatments is required in order to advance MS therapeutics. Although remyelination is the most obvious approach by which to promote regeneration in MS, we should also consider what realistically can be achieved with such treatment. Remyelinating therapies seem unlikely to yield a consistently improved outcome after an acute relapse, as many relapses recover well clinically and, where functional impairment does ensue, the deficits are probably due not only to demyelination, but also to other factors such as axonal degeneration or dysfunction. Remyelination is most effective immediately after damage and thus remyelinating treatment should, rationally, be initiated immediately after a relapse-or at least early in the course of the disease in patients who are experiencing clinical or paraclinical signs of incomplete repair. Another fundamental question that has not yet been addressed is whether the molecular processes governing remyelination are the same in all patients. The immunological process leading to demyelination might vary between patients 103 , and consequently differences might also exist in how remyelination can be enhanced.
Currently, how remyelination might best be measured in a clinical trial is unclear and new imaging methods need to be developed and applied for this purpose. At the same time, we also need better-defined clinical end points for clinical trials. The favoured site of interrogation in MS trials is currently the visual system, with focus on the clinical presentation of optic neuritis owing to the fact that we can define outcome fairly accurately both from a clinical and a paraclinical perspective. One caveat in focusing on optic neuritis is that MRI is difficult in the optic nerve, which poses a problem as MRI outcome measures have become an essential component for judging the efficacy of immunomodulatory therapies in MS trials.
In principle, spinal cord lesions after myelitis would be another good region to focus on for clinical trials of remyelinative therapies, as clinical symptoms can be easily localized to the spinal cord, neurophysiological measurements are available, and the region is accessible for MRI. However, to effectively interrogate therapeutic responsiveness using the spinal cord as a region of interest, we need to acquire more information concerning how lesions develop within the spinal cord, as most MRI studies investigating remyelination have been performed in the brain. Importantly, remyelinating therapies are also being tested in other contexts -for example in children with Pelizaeus-Merzbarcher disease 104 -and success in these contexts would provide a rationale for fast-tracking of follow-up clinical trials in people with MS.
Assessment of the enduring clinical benefits of remyelin ation will be required, beyond the paraclinical bene fits identified in short-term proof-of-principle studies. The definitive identification of clinical benefits would require long-term trials that might not be practical. Whether other approaches such as registry-based, long-term observational studies using propensity matching will provide meaningful insights in this regard remains uncertain 105 . In summary, development of a remyelinating treatment that can enhance the natural repair process in MS is a rational goal. Several important questions remain unanswered, including the best molecular target, the best method to measure short-term responsiveness, and how to interrogate any long-term clinical benefit. Nevertheless, there is cause for optimism that we will solve these questions in the years to come. Once available, remyelinating treatments will complement immuno modulation by inducing repair and potentiating neuroprotection to improve long-term outcome in MS.
